Malaria, caused by Plasmodium parasites, remains one of the most devastating infectious
diseases worldwide, despite control efforts to lower morbidity and mortality. Both advanced …

New strategies are needed to reduce the incidence of malaria, and promising approaches
include vaccines targeting the circumsporozoite protein (CSP). To improve upon the malaria …

Malaria is a major public health concern, as a highly effective human vaccine remains
elusive. The efficacy of a subunit vaccine targeting the most abundant protein of the …

The leading malaria vaccine in development is the circumsporozoite protein (CSP)-based
particle vaccine, RTS, S, which targets the pre-erythrocytic stage of Plasmodium falciparum …

Mouse models are useful for the early down-selection of malaria vaccine candidates. The
Walter Reed Army Institute of Research has optimized a transgenic Plasmodium berghei …

Preerythrocytic vaccines prevent malaria by targeting parasites in the clinically silent
sporozoite and liver stages and preventing progression to the virulent blood stages. The …

Abstract Development of next-generation vaccines against Plasmodium falciparum (Pf) is a
priority. Many malaria vaccines target the pre-erythrocytic sporozoite (SPZ) and liver stages …

The circumsporozoite protein (CSP) of Plasmodium falciparum is a major surface protein,
which forms a dense coat on the sporozoite's surface. Preclinical research on CSP and …

Malaria, which is the result of Plasmodium falciparum infection, is a global health threat that
resulted in 655,000 deaths and 216 million clinical cases in 2010 alone. Recent phase 3 …

There is a pressing need for safe and highly effective Plasmodium falciparum (Pf) malaria
vaccines. The circumsporozoite protein (CS), expressed on sporozoites and during early …